EP3880176A4 - SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES DUE TO REDUCED BONE DENSITY OR CARTILAGE LOSS AND THEIR USES - Google Patents

SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES DUE TO REDUCED BONE DENSITY OR CARTILAGE LOSS AND THEIR USES Download PDF

Info

Publication number: EP3880176A4
Authority: EP; European Patent Office
Prior art keywords: sustained; treatment; pharmaceutical compositions; therapeutic agent; bone density
Prior art date: 2018-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19884612.3A

Other languages

German (de)

French (fr)

Other versions

EP3880176A1 (en

Inventor

Keelung Hong

Hao-Wen Kao

Yi-Yu Lin

Jonathan FANG

Weiwei FANG

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taiwan Liposome Co Ltd

TLC Biopharmaceuticals Inc

Original Assignee

Taiwan Liposome Co Ltd

TLC Biopharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-11-14

Filing date

2019-11-13

Publication date

2022-08-03

2019-11-13 Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd

2021-09-22 Publication of EP3880176A1 publication Critical patent/EP3880176A1/en

2022-08-03 Publication of EP3880176A4 publication Critical patent/EP3880176A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)

EP19884612.3A 2018-11-14 2019-11-13 SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES DUE TO REDUCED BONE DENSITY OR CARTILAGE LOSS AND THEIR USES Withdrawn EP3880176A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862767254P	2018-11-14	2018-11-14
PCT/US2019/061143 WO2020102323A1 (en)	2018-11-14	2019-11-13	Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof

Publications (2)

Publication Number	Publication Date
EP3880176A1 EP3880176A1 (en)	2021-09-22
EP3880176A4 true EP3880176A4 (en)	2022-08-03

Family

ID=70730604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19884612.3A Withdrawn EP3880176A4 (en)	2018-11-14	2019-11-13	SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES DUE TO REDUCED BONE DENSITY OR CARTILAGE LOSS AND THEIR USES

Country Status (5)

Country	Link
EP (1)	EP3880176A4 (en)
JP (1)	JP7431419B2 (en)
CN (1)	CN113056259A (en)
TW (1)	TWI729562B (en)
WO (1)	WO2020102323A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101199505A (en) *	2007-12-20	2008-06-18	沈阳药科大学	Verapamil liposome and preparation method thereof
CN102406606A (en) *	2011-11-29	2012-04-11	海南美大制药有限公司	Quetiapine fumarate liposome solid preparation
US20130202686A1 (en) *	2010-12-27	2013-08-08	Terumo Kabushiki Kaisha	Liposome composition and process for production thereof
WO2017066726A1 (en) *	2015-10-16	2017-04-20	Merrimack Pharmaceuticals, Inc.	Stabilizing camptothecin pharmaceutical compositions
WO2017193139A1 (en) *	2016-05-06	2017-11-09	The Brigham And Women's Hospital, Inc.	Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
US9877918B2 (en) *	2011-03-25	2018-01-30	Terumo Kabushiki Kaisha	Long-lasting controlled-release liposome composition and method for producing same
WO2020023445A1 (en) *	2018-07-24	2020-01-30	Taiwan Liposome Co., Ltd.	Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8658203B2 (en) *	2004-05-03	2014-02-25	Merrimack Pharmaceuticals, Inc.	Liposomes useful for drug delivery to the brain
AU2006302797B2 (en)	2005-03-02	2012-02-02	Merck Canada Inc.	Composition for inhibition of cathepsin K
CA2834968C (en) *	2011-01-05	2018-01-09	Livon Laboratories	Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
EP2537532A1 (en)	2011-06-22	2012-12-26	J. Stefan Institute	Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
EP2734500A4 (en) *	2011-07-20	2015-04-08	Gen Hospital Corp	SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 FOR THE TREATMENT OF BONE DISEASE
SI2854769T1 (en) *	2012-07-05	2023-09-29	Taiwan Liposome Company, Ltd.	Methods of treating arthritis
WO2014121211A2 (en) *	2013-02-01	2014-08-07	Zoneone Pharma, Inc.	Remote loading of sparingly water-soluble drugs into liposomes

2019
- 2019-11-13 EP EP19884612.3A patent/EP3880176A4/en not_active Withdrawn
- 2019-11-13 WO PCT/US2019/061143 patent/WO2020102323A1/en not_active Ceased
- 2019-11-13 TW TW108141107A patent/TWI729562B/en not_active IP Right Cessation
- 2019-11-13 CN CN201980074616.4A patent/CN113056259A/en active Pending
- 2019-11-13 JP JP2021525745A patent/JP7431419B2/en active Active

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101199505A (en) *	2007-12-20	2008-06-18	沈阳药科大学	Verapamil liposome and preparation method thereof
US20130202686A1 (en) *	2010-12-27	2013-08-08	Terumo Kabushiki Kaisha	Liposome composition and process for production thereof
US9877918B2 (en) *	2011-03-25	2018-01-30	Terumo Kabushiki Kaisha	Long-lasting controlled-release liposome composition and method for producing same
CN102406606A (en) *	2011-11-29	2012-04-11	海南美大制药有限公司	Quetiapine fumarate liposome solid preparation
WO2017066726A1 (en) *	2015-10-16	2017-04-20	Merrimack Pharmaceuticals, Inc.	Stabilizing camptothecin pharmaceutical compositions
WO2017193139A1 (en) *	2016-05-06	2017-11-09	The Brigham And Women's Hospital, Inc.	Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
WO2020023445A1 (en) *	2018-07-24	2020-01-30	Taiwan Liposome Co., Ltd.	Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Preparation and pharmacokinetic investigation of propranolol-loaded elastic liposomes composed of DP-PC and SPC", CHINESE PHARMACEUTICAL JOURNAL, ZHONGGUO YAOXUEHUI ZHUBAN CHUBAN. ZHONGGUO-YAOXUE-ZAZHI BIANJI WEIYUANHUI, CN, vol. 48, no. 20, 22 October 2013 (2013-10-22), pages 1761 - 1765, XP009534476, ISSN: 1001-2494 *
EL-MEZAYEN NESRINE S ET AL: "Hepatic stellate cell-targeted imatinib nanomedicineversusconventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 28 September 2017 (2017-09-28), pages 226 - 237, XP085292753, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.035 *
KIM HYEONGSEOK ET AL: "Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 678, no. 1, 23 November 2011 (2011-11-23), pages 55 - 60, XP028891080, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2011.12.017 *
SATO TSUYOSHI ET AL: "Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase", HELIYON, vol. 1, no. 1, 1 September 2015 (2015-09-01), GB, pages e00013, XP055935707, ISSN: 2405-8440, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939821/pdf/main.pdf> DOI: 10.1016/j.heliyon.2015.e00013 *
See also references of WO2020102323A1 *
TAKAMATSU AKIRA ET AL: "Verapamil Protects against Cartilage Degradation in Osteoarthritis by Inhibiting Wnt/[beta]-Catenin Signaling", PLOS ONE, vol. 9, no. 3, 21 January 2014 (2014-01-21), pages e92699, XP055935688, DOI: 10.1371/journal.pone.0092699 *
TORU HIRAGA ET AL: "Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals", INTERNATIONAL JOURNAL OF CANCER, vol. 124, no. 1, 1 January 2009 (2009-01-01), US, pages 215 - 222, XP055292283, ISSN: 0020-7136, DOI: 10.1002/ijc.23903 *
ZHANG XINGGUANG ET AL: "Propranolol Prevents Osteoporosis and up-regulates Leptin in Ovariectomized Rats", IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR, 1 January 2013 (2013-01-01), Iran, pages 557 - 562, XP055935721, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813260/pdf/ijpr-12-557.pdf> [retrieved on 20220627] *

Also Published As

Publication number	Publication date
TW202031247A (en)	2020-09-01
TWI729562B (en)	2021-06-01
EP3880176A1 (en)	2021-09-22
WO2020102323A1 (en)	2020-05-22
CN113056259A (en)	2021-06-29
JP2023510658A (en)	2023-03-15
JP7431419B2 (en)	2024-02-15

Legal Events

Date	Code	Title	Description
2020-05-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-08-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-08-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-09-22	17P	Request for examination filed	Effective date: 20210512
2021-09-22	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-02-23	DAV	Request for validation of the european patent (deleted)
2022-02-23	DAX	Request for extension of the european patent (deleted)
2022-06-30	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0009000000 Ipc: A61K0009127000
2022-08-03	A4	Supplementary search report drawn up and despatched	Effective date: 20220706
2022-08-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 47/26 20060101ALI20220630BHEP Ipc: A61K 47/02 20060101ALI20220630BHEP Ipc: A61P 35/00 20060101ALI20220630BHEP Ipc: A61K 31/496 20060101ALI20220630BHEP Ipc: A61K 9/00 20060101ALI20220630BHEP Ipc: A61K 31/495 20060101ALI20220630BHEP Ipc: A61K 9/127 20060101AFI20220630BHEP
2025-09-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2025-10-15	18D	Application deemed to be withdrawn	Effective date: 20250603

Publication	Publication Date	Title
EP3830259A4 (en)	2022-05-04	MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
EP3810601A4 (en)	2022-04-20	PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CANCERS COMPRISING THEM
MA51739A (en)	2020-12-16	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3463304A4 (en)	2020-01-08	COMPOSITIONS COMPRISING CANNABIDIOL AND HYALURONIC ACID FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES
EP3639833A4 (en)	2021-03-10	AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO FAT AND / OR INFLAMMATION
MA53665B1 (en)	2025-09-30	FARNESOID X RECEPTOR AGONISTS AND THEIR USES
EP3934646A4 (en)	2022-12-14	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES OR DISORDERS
EP3498279A4 (en)	2020-04-29	PHARMACEUTICAL COMPOSITION COMPRISING AS ACTIVE INGREDIENTS OF AMODIAQUINE AND AN ANTI-DIABETES MEDICINE FOR THE PREVENTION OR TREATMENT OF DIABETES
EP3737376A4 (en)	2021-10-27	SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
EP3826615A4 (en)	2022-05-04	SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DEMENTIA, AND THEIR USES
EP3841086A4 (en)	2022-07-27	PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS
EP3876967A4 (en)	2022-11-23	THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND/OR PREVENTION OF DYSBIOSIS
MA50905A (en)	2020-09-23	COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
EP3791869A4 (en)	2022-03-09	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES COMPRISING THE COX2 ACETYLATING AGENT AS ACTIVE INGREDIENT
EP3877383A4 (en)	2022-09-21	COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
EP3362096A4 (en)	2019-06-12	OPHTHALMIC TREATMENT COMPOSITION AND VEHICLE FOR THE ADMINISTRATION OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTIC AGENTS
MA54522A (en)	2022-03-23	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EP3804736A4 (en)	2022-03-30	PHARMACEUTICAL COMPOSITION COMPRISING MESENCHYMATOUS STEM CELLS AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE
EP3804739A4 (en)	2022-03-23	COMPOSITION COMPRISING AN EXTRACT OF ASTER SPHATHULIFOLIUS MAXIM FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF MUSCLE DISEASES OR FOR THE IMPROVEMENT OF MUSCLE FUNCTIONS
MA55872A (en)	2022-03-16	ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR THE TREATMENT OF OCULAR DISEASES
EP3829539A4 (en)	2022-05-04	EXTENDED RELEASE COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
MA39447B1 (en)	2018-05-31	Pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3880709A4 (en)	2022-07-27	ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR THE TREATMENT OF CANCER
EP3827831A4 (en)	2022-04-06	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
EP3785718A4 (en)	2022-01-12	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN INFECTIOUS FLAVIVIRUS DISEASE